BioSig Technologies, Inc. announced that Mayo Clinic-Phoenix-an existing user of the PURE EP Platform- has upgraded to the Platform's subscription model to gain immediate access to the Company's latest technological advancements in cardiac arrhythmia identification. Harnessing the power of automation, PURE EP 's latest software features debut unique algorithms that unlock signal data for electrophysiologists conducting even the most challenging ablation procedures. Automatic Tachycardia Characterization (ATC) alerts electrophysiologists to heart conduction patterns that may be difficult to detect with the naked eye or that might warrant further evaluation.

Near-Field Tracking (NFT) monitors changes in the local unipolar electrogram to provide real-time tissue feedback that assists electrophysiologists as they make their final determinations between healthy and scarred tissue for lesion placement during an ablation. Mayo Clinic-Phoenix is ranked as the number one hospital in Arizona, according to the U.S. News and World Report. Within the specialty of cardiology, heart, and vascular surgery, the institution is ranked in the top one% of hospitals nationwide (33 out of 4,515 hospitals).

With Mayo Clinic-Phoenix and Cleveland Clinic now part of the PURE EP subscriber community, two out of the top three ranked health systems in cardiology, heart, and vascular surgery have embraced PURE EP. The Company's product, the PURE EP platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency and efficacy.